RE:RE:RE:CountdownI doubt very much that we would see the same deal, Rosie. That deal was cancelled before the AGM. But I do question what Midatech, LT and the new investors are up to. It wouldn't surprise me to see another Midatech/Biodexa deal appear. It could be similar to the previous arrangement or it could be a licensing deal, an xB3 asset sale to Biodexa or any of many other possibilities.
I worry about two larger possibilities:
A) The sale of Bioasis to a private company or near private concern like Biodexa. Bioasis shareholders would receive very little and would very little upside opportunity, especially if xB3 is then sold to a third entity, likely private.
B) Bioasis sells the xB3 Platform and keeps EGF and a few small xB3 licenses like LSDs and/or EGF. These licenses pale in value compared to brain tumours, neurodegenerative diseases, and neuroinflammatory conditions.
In either case, some Bioasis management and BoD would likely join the buyer as with the previous deal. They could benefit despite having destroyed Bioasis.
I don't have any faith that Rathjen can or will make a winner out of Bioasis. I would love to be wrong about that
jd